This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SHOW MORE NRx Pharmaceuticals advances NRX-100, a preservative-free ketamine, through a fast-tracked FDA review for treating suicidal depression and PTSD. Sanom/Adobestock BREAKING NEWS A new formulation of ketamine is progressing through a novel US Food and Drug Administration review pathway, announced NRx Pharmaceuticals.
Depression was sold to us as a simple problem of serotonin insufficiency, a convenient narrative that made drug companies like Eli Lilly, Forest Pharmaceuticals, and Pfizer very rich. As a former pharmaceutical advertising writer, I not only witnessed the explosive growth in antidepressant drugs, I contributed to it.
NRx Pharmaceuticals seeks FDA approval for NRX-100, a preservative-free ketamine for suicidal depression and PTSD, via the National Priority Voucher pathway. A recently filed patent on its preservative-free manufacturing process may further support market exclusivity.
June 24, 2025 Centanafadine — a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) — is effective at treating ADHD in adults, adolescents, and children, according to Phase 3 trials sponsored by the drug’s manufacturer, Otsuka Pharmaceuticals.
The journal continued to be in good hands, and thus one of the few journals that was receptive to research findings that belied the narrative of therapeutic progress that the psychiatric guild and pharmaceutical companies have been promoting for decades. He noted too the reluctance of the field to consider this possibility.
Establishment psychiatry has shown this same unscientific thinking in its manufacturing of other biological theories of mental illness. The APA publishes the DSM diagnostic manual, and PLOS Medicine reported in 2012, 69% of the DSM- 5 task force members report having ties to the pharmaceutical industry.
My brain and my life are dependent upon a pharmaceutical company in India staying in business and manufacturing generic duloxetine until the day I die. I also get withdrawal if I try to switch brands, and I have no idea if my brain would eventually accept and stabilize on a new brand.
Maine) introduced a bill Thursday that would ban pharmaceuticalmanufacturers from using direct-to-consumer advertising, including social media, to promote their products. They want us to take on the greed of the pharmaceutical industry and ban these bogus ads.” From The Wall Street Journal : “Sens. Bernie Sanders (I.,
Stephenson and a team of researchers from various academic and pharmaceutical institutions, including the University of Virginia School of Medicine. Maelys Touya was an employee of Lundbeck LLC, and Lambros Chrones was an employee of Takeda Pharmaceuticals U.S.A., The study was authored by Judith J. Additionally, Anita H.
From The Guardian : “In 2017, the Cherokee Nation became the first tribe to file a lawsuit against opioid manufacturers and distributors for promoting the flow of prescription opioids into its community.
Schatzberg has served as a consultant to or received honoraria from Abbott, Bristol-Myers Squibb, Corcept Therapeutics, Forest Laboratories, Janssen, Eli Lilly, Merck, Mitsubishi Pharmaceuticals, Organon, ParkeDavis, Pfizer, Pharmacia–Upjohn, Sanofi, Scirex, SmithKline Beecham, Solvay, and Wyeth–Ayerst.
However, in the summer of 1990, the Prozac story started to come undone, and it was then that the pharmaceutical industry, in concert with its thought leaders from academic psychiatry, plotted the strategy that has successfully cowed the mainstream media ever since.
For the pharmaceutical industry, the bigger and wider those diseases, the more people who can be diagnosed, and the bigger your markets are. The marketing of medical conditions has become a key plank of pharmaceutical industry marketing. Helping widen the definitions of disease is a key part of marketing those pharmaceutical products.
But the person prescribing them (or manufacturing them) has a different problem to solve: explaining why I should still trust them to guide me to wellness. The therapy to which they referred was entirely pharmaceutical—it was always a failure to improve with medication. The depression eggs are all in one pharmaceutical basket.
Doctors became hypnotized by the appearance of “science”, even if the literature they consulted was essentially pharmaceutical advertising. Such optimism would be disappointed by dwindling pharmaceutical progress in the later half of the century. When medications did cause harm, the doctors were completely blind to it.
Somatics LLC marked a watershed moment for advocates who have fought for decades for ECT device manufacturer accountability. The Himes decision “clarifies a gap in the law that the pharmaceutical industry has exploited for decades,” said plaintiff’s attorneys Wisner Baum in a statement.
There was no placebo group, and all patients started on citalopram, manufactured by Lundbeck, which was motivated by horrendously erroneous claims of citalopram’s “absence of discontinuation symptoms” and its “safety” in elderly patients. Nothing in Insel’s narrative would harm psychiatry’s guild interests or pharmaceutical interests.
The toxic pills distributed en masse by the pharmaceutical behemoths have led to more deaths in the U.S. While psychiatrists are culpable as the pushers of these brain-altering nightmare pills, the industry that manufactures and promotes them (AKA Big Pharma) deserves their own Nuremberg. than the Vietnam War. See article HERE
However, rather than people becoming enraged and politically engaged to change carcinogenic environments, an extremely powerful medical-pharmaceutical industrial complex has controlled the societal narrative to focus—not on eliminating environmental-societal causes of cancer—but on expensive cancer treatments. between 1990 and 2019.”
With the explosion of more and more drugs in cabinets across the country, more and more children are dying—but still, pharmaceutical companies push their products, leading to yet more drugs and yet more deaths. Unlike the pharmaceutical industry, in our village community the pain of losing a single child was felt by all.
Polly was deposited at Harlem Valley at the start of the early wave of patients being treated with new drugs churned out by a booming pharmaceutical industry and prescribed enthusiastically by doctors. drug companies manufactured enough barbiturates in 1955 alone to treat 10 million people daily throughout the year.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content